X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Stemline will have the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico’s AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Stemline Therapeutics
Deal Size: $512.0 million Upfront Cash: $12.0 million
Deal Type: Licensing Agreement January 04, 2024
Details:
Under the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, a best-in-class small molecule inhibitor of USP1, as a synthetic lethal target in the context of BRCA-mutated tumors, and other USP1-targeting compounds.
Lead Product(s): ISM3091
Therapeutic Area: Oncology Product Name: ISM3091
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 12, 2023
Details:
ISM3312 is a highly selective 3CLpro inhibitor with a novel molecular structure optimized from compounds designed by Chemistry42, Insilico’s generative chemistry AI platform for the treatment of COVID-19.
Lead Product(s): ISM3312
Therapeutic Area: Infections and Infectious Diseases Product Name: ISM3312
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
INS018_055 is the first anti-fibrotic small molecule inhibitor, generated by Insilico's Pharma.AI drug discovery platform, which targets major activated signaling cascades that significantly contribute to the pathogenesis idiopathic pulmonary fibrosis.
Lead Product(s): ISM001-55
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INS018_055
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Under the terms of the agreement, the collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,221.5 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 08, 2022
Details:
Capital raised in the round will further bolster Insilico's financial position and fuel the growth of its advancing pipeline, including its lead program ISM001-55 (INS018_055) which is currently in a Phase I study, and continued development of its Pharma.AI platform.
Lead Product(s): ISM001-55
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: INS018_055
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: BHR Partners
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing June 06, 2022
Details:
Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Preclinical candidate targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
Insilico's PCC molecule, ISM025 demonstrated potential when targeted against a broad range of tumor lineages with HRD backgrounds. In vitro data showed potent anti-proliferation activity of the compound in BRCA-mutant tumor cells with excellent selectivity.
Lead Product(s): ISM025
Therapeutic Area: Oncology Product Name: ISM025
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
The collaboration will combine Insilico's Pharma.AI platform to advance de novo small molecule design and generation with EQRx's clinical development and commercialization expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: EQRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
